Glucagon was administered to I3 infants and children with advanced atrioventricular block. The drug produced a positive response in 12 incompletely studied in subjects with advanced atrioventricular heart block. Dogs with acute and chronic acquired atrioventricular heart block showed a positive response after glucagon administration (Hurwitz, 197I). Adults with acquired block and fixed-rate pacemakers responded to intravenous injections of glucagon with an increase in cardiac output (Ashley et al., I970). Recent studies in adults with chronic atrioventricular heart block have been contradictory (Gavrilescu et al., 1971; Nishimura, Fortner, and Williams, I972).
Glucagon has been shown to possess positive chronotropic and inotropic responses in subjects with either normal or abnormal cardiovascular systems (Parmley and Sonnenblick, I97I; Linhart et al., I968; Glick et al., I968; Parmley, Glick, and Sonnenblick, I968; Nord, Fontanes, and Williams, I970; Williams et al., I969). Despite its recognized chronotropism, glucagon has been incompletely studied in subjects with advanced atrioventricular heart block. Dogs with acute and chronic acquired atrioventricular heart block showed a positive response after glucagon administration (Hurwitz, 197I) . Adults with acquired block and fixed-rate pacemakers responded to intravenous injections of glucagon with an increase in cardiac output (Ashley et al., I970) . Recent studies in adults with chronic atrioventricular heart block have been contradictory (Gavrilescu et al., 1971; Nishimura, Fortner, and Williams, I972) .
The purpose of this study is to present the initial cardiovascular data obtained after administration of glucagon to infants and children with advanced atrioventricular heart block, either congenital, postoperative, or metabolic in origin.
Patients and methods Glucagon was administered to 13 patients with cardiac arrhythmias, predominantly atrioventricular dissociation and bradycardia (Fig. i) . Their ages ranged from 2 days to I6 years (Table) . In the ii patients in whom complete atrioventricular heart block was the dominant rhythm, an attempt was made to distinguish between a junctional and an idioventricular pacemaker. The latter was considered present when there was atrioventricular dissociation, bradycardia, and a slurred QRS complex of prolonged duration. By these criteria, 5 patients had complete atrioventricular heart block with pacing stimulus probably distal to junctional tissue, and 6 had complete block with junctional pacemaking. One patient had a i: i atrial-ventricular response and junctional rhythm, and one had second-degree block with a 2: I atrial-ventricular response. Arrhythmia was surgically acquired in 4 cases and was congenital in 8. Case I2 had a severe metabolic disturbance with acidosis and congestive failure probably caused by sepsis.
Before glucagon administration, informed consent was obtained by discussing the use of the drug with the family of each patient. It was explained that glucagon had been used to treat hypoglycaemia in many infants and children as well as being used as a cardiotonic drug for many adult patients. The cardiac effects of glucagon were to be studied to determine possible effectiveness of the drug in symptomatic atrioventricular heart block. If effective it could then be administered as a temporary agent during critical periods, such as pacemaker implantation. The research protocol was submitted to and approved by the Committee for Human Research at Indiana University Medical School before the project was begun.
The effect of glucagon was studied during the course of diagnostic cardiac catheterization in 6 patients. Right and left heart catheterization was routinely performed. Older children were sedated with a mixture of pethi- The difference in ventricular rate before and after glucagon was analysed by Student's t-test for paired data. The time course for intravenous glucagon response was obtained by polynomial regression analysis.
Results
The ventricular rate increased in I2 patients after glucagon administration (Fig. 2) . Only Case 5, given glucagon intramuscularly, showed no response. In patients with complete atrioventricular heart block the mean resting ventricular rate was 58 beats a minute. The mean maximal ventricular rate after parenteral glucagon was 67 beats a minute. The mean difference was statistically significant (P <o-ooi). The onset of action was early in all cases. The maximal effect was frequently at 2 to S minutes. Though this chronotropic response persisted beyond i5 minutes in a few cases, the significant effect generally lasted io to i5 minutes (Fig. 3) . Isoprenaline infision increased the ventricular rate to similar or slightly higher levels than did glucagon in 4 patients. However, in 2 patients isoprenaline produced chging rhythms, including bigeminy and multiple ventricular foci. Blood glucose values, determined in 3 patients, rose by 20 to 40 mg/Ioo ml. Potassium levels remained within 0-3 mEq/l. of the control level. Case 3 was the only patient who had side effects.
Discussion
Heart block accompanied by bradycardia is often life threatening to an infant or child, especially when it arises at the time of corrective operation or is associated with additional malformations of the heart (Lillehei et al., I963; Nakamura and Nadas, I964). The low resting ventricular rate and the inability of the heart to respond to stress with tachycardia may produce an insufficient cardiac output, myocardial hypoxia, and a more devastating arrhythmia such as ventricular fibrillation. Since glucagon has been shown to possess cardiotonic properties and has been safely employed for many years in the treatment of symptomatic hypoglycaemia in infancy, it seemed appropriate to evaluate the drug in paediatric patients with bradyarrhythmias.
Of I3 patients in this study, ii had complete atrioventricular heart block. His bundle recording to determine the exact site of pacemaking impulse was not employed, though the pacemaking origin appeared to be idioventricular in 5 patients. Resting ventricular rates in some cases were higher than those commonly seen with complete atrioventricular heart block; however, these patients were infants or children in the immediate postoperative period. This type of patient usually has a ventricular rate well over ioo beats a minute.
Data accumulated in the present study indicate a positive chronotropic response to single bolus intravenous injections of glucagon. The 20 per cent increase in maximal ventricular rate is similar to the rate increment seen both in normal adults and in those with a compromised cardiovascular system (Parmley and Sonnenblick, I97I; Linhart et al., I968) . The adrenergic agent isoprenaline was administered to 4 patients and resulted in rate increases of the same magnitude as those seen with glucagon. However, isoprenaline resulted in further worrisome arrhythmias in 2 patients. The response to glucagon was almost immediate, with peak effects between 3 and I0 minutes. Though the rate was modestly raised for 20 minutes in a few cases, the major effect was dissipated within I5 minutes. A succeeding dose of glucagon was administered twice with only an 8 per cent further increment in rate after initial increases of I7 and 22 per cent. Cardiac output rose in the 4 patients so tested, but only slightly in one (Case 2); however, this extremely obese youngster received only 0-02 mk/kg glucagon. The average increment in cardiac output was similar to previously reported data in adults without heart block (Parmley and Sonnenblick, I97I; Linhart et al., I968) . Interestingly, results from the two studies of glucagon in adults with atrioventricular heart block have been contradictory. In one (Nishimura et al., I972) glucagon administration did not significantly affect the rate of the spontaneous pacemaker. On the other hand, Gavrilescu et al. (I97I) found that glucagon increased the ventricular rate in adults with chronic atrioventricular heart block.
The mechanism by which glucagon produces positive chronotropism has not been delineated. The drug has increased ventricular automaticity in vitro and in vivo (Stewart, Myerburg, and Hoffman, I969; Wilkerson, Pruett, and Woods, I97I; Lucchesi, I968) . Glucagon has also been shown to reverse quinidine-induced decreases in action potential. The augmented automaticity was not catecholamine dependent, since propranolol did not block glucagon's action (Wilkerson et al., 1971 ).
In this study, patients with an apparent pacing site in junctional tissues and those whose pacemaking site appeared to be distal to the atrioventricular node had similar responses to glucagon. Furthermore, those with congenital atrioventricular block and those with surgically acquired block responded similarly. Infants and older children had similar responses to glucagon administered according to weight. Unfortunately, clinical improvement could not be evaluated in these patients, since for the most part they received only single bolus injections of the drug.
The usual dosage of glucagon in this study was that commonly employed (Parmley and Sonnen- 
